Herpes simplex virus expressing foreign genes and method for treating cancers therewith

• US 6,764,675 B1
• Filed: 02/14/2002
• Issued: 07/20/2004
• Est. Priority Date: 06/08/1999
• Status: Expired due to Fees

• Current Assignee: UAB Research Foundation (University of Alabama System)
• Original Assignee: UAB Research Foundation (University of Alabama System)
• Inventors: Whitley, Richard J., Markert, James MacDowell, Gillespie, George Yancey, Parker, Jacqueline Ness
• Primary Examiner(s): PRIEBE, SCOTT DAVID
• Application Number:
  US10/009,972
• Time in Patent Office: 887 Days
• Field of Search: 424/93.2, 514/44, 435/320.1, 435/455, 435/456
• US Class Current: 424/93.2
• CPC Class Codes: A61K 35/763 Herpes virus
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 38/208 IL-12
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/16632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/16643 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2830/00 Vector systems having a special element relevant for transcription
• CPC Class Codes: C12N 2830/85 mammalian
• CPC Class Codes: C12N 2840/203 having an IRES
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12N 9/78 acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Abstract

An anti-cancer pharmaceutical composition includes a herpes simplex virus (HSV) vector into which a nucleic acid sequence encoding an anti-cancer agent selected from interleukin-12, GM-CSF, and CD has been inserted. A method of treatment of a patient suffering from cancer includes administering to the patient the anti-tumor pharmaceutical composition including an HSV vector having a nucleic acid sequence encoding an anti-cancer agent selected from interleukin-12, GM-CSF, and CD inserted therein.

Claims

1. An anti-tumor pharmaceutical composition comprising a replication competent herpes simplex virus vector comprising a nucleic acid sequence encoding cytosine deaminase operatively linked to a promoter, and a pharmaceutically acceptable carrier.

2. A pharmaceutical composition according to claim 1, wherein said HSV vector is substantially aneurovirulent.

5. A pharmaceutical composition according to claim 1, wherein the expression of the nucleic acid sequence encoding cytosine deaminase results in constitutive production of cytosine deaminase in vivo.

3. An anti-tumor pharmaceutical composition comprising a herpes simplex virus vector comprising a nucleic acid sequence encoding cytosine deaminase operatively linked to a promoter, and a pharmaceutically acceptable carrier, wherein the vector comprises a deletion of the γ

₁34.5 gene.

4. An anti-tumor pharmaceutical composition comprising a herpes simplex virus vector comprising a nucleic acid sequence encoding cytosine deaminase operatively linked to a promoter, and a pharmaceutically acceptable carrier, wherein the sequence is inserted within the γ

₁34.5 gene deletion.